<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606032</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 0163</org_study_id>
    <nct_id>NCT02606032</nct_id>
  </id_info>
  <brief_title>Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis</brief_title>
  <acronym>FMT</acronym>
  <official_title>Randomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamilton Academic Health Sciences Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that giving antibiotics prior to fecal transplant&#xD;
      therapy for active UC increases the proportion of patients in remission at the end of&#xD;
      treatment. The investigators will randomize patients aged 18 or over with active UC to&#xD;
      antibiotics (metronidazole 500mg, doxycycline 100mg, Terbinafine 250 mg, all twice daily for&#xD;
      two weeks); or identical placebo. At the end of two weeks the investigators will give all&#xD;
      patients fecal transplant therapy twice per week for eight weeks from an anonymous donor&#xD;
      stool.). Patients will complete a validated UC questionnaire, have a flexible sigmoidoscopy&#xD;
      to assess the degree of inflammation in the colon and complete general and disease specific&#xD;
      quality of life questionnaire as well as a questionnaire on anxiety and depression. Patients&#xD;
      will complete the same questionnaires again at the end of treatment at week 9 when they will&#xD;
      also have a repeat flexible sigmoidoscopy. The main outcome that will be assessed is the&#xD;
      proportion of patients in remission from their UC at the end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients aged 18 or over with active UC defined as a Mayo score &gt; 3 with an endoscopic score&#xD;
      &gt;0 will be eligible for the study. Subjects will be excluded if they are participating in&#xD;
      another clinical trial, are unable to give informed consent, have severe comorbid medical&#xD;
      illness, have concomitant Clostridium difficile infection or have severe UC requiring&#xD;
      hospitalization. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNFα&#xD;
      therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to&#xD;
      randomization. Eligible patients will be randomized 1:1 to metronidazole 500mg bid,&#xD;
      doxycycline 100mg bid, Terbinafine 250 mg and or identical placebos all for two weeks.&#xD;
      Patients will all then receive their first FMT 1-3 days after completing their course of&#xD;
      antibiotic/placebo. FMT will be administered twice per week for 8 weeks.&#xD;
&#xD;
      Eighty active UC patients will be randomized 1:1 according to a computer generated&#xD;
      randomization list. Randomization will be administered centrally at the GI Clinical Trials&#xD;
      Unit to ensure concealment of allocation.&#xD;
&#xD;
      Subjects will have a sigmoidoscopy (or colonoscopy if clinically indicated), physician&#xD;
      assessment and complete a Mayo score, IBDQ questionnaire, EQ5D and HAD questionnaires at&#xD;
      baseline. A repeat sigmoidoscopy, Mayo score, IBDQ, EQ5D and HAD questionnaires will be&#xD;
      completed at 9 weeks, at exit from the study (one week after last FMT). No new medical&#xD;
      therapies (e.g. corticosteroids, antibiotics, probiotics) will be permitted during the 9 week&#xD;
      study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the randomized trial is remission of UC defined as a Mayo score &lt; 3 with an endoscopic Mayo score = 0 at the end of the trial Transplant Therapy in Ulcerative Colitis</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Metronidazole+doxycylcine+terbinafine</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical placebos to all antibiotics</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 or over&#xD;
&#xD;
          2. Active UC defined as a Mayo score &gt; 3&#xD;
&#xD;
          3. A Mayo endoscopic score &gt; 0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in another clinical trial&#xD;
&#xD;
          2. Unable to give informed consent&#xD;
&#xD;
          3. Severe co-morbid medical illness&#xD;
&#xD;
          4. Concomitant Clostridium difficile infection&#xD;
&#xD;
          5. Severe UC requiring hospitalization.&#xD;
&#xD;
          6. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with&#xD;
             5-ASA, azathioprine, 6-mercaptopurine or anti-TNF alpha therapy (e.g. infliximab) will&#xD;
             be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on&#xD;
             a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will&#xD;
             also be permitted provided the dose of steroid is not increased again. Stable intake&#xD;
             of probiotic therapy also permitted.&#xD;
&#xD;
          7. Antibiotic therapy in the last 30 days.&#xD;
&#xD;
          8. Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Moayyedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton HSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences / McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Paul Moayyedi</investigator_full_name>
    <investigator_title>Director Division of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplant</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

